Cancer Research

Cancer cells

Combo therapy may benefit some paediatric cancer patients

18 April 2023

A combination of the PARP inhibitor olaparib (Lynparza) and the investigational ATR inhibitor ceralasertib showed clinical benefit in paediatric patients with solid tumours exhibiting DNA replication stress and/or DNA repair deficiencies, according to new data. The results from the Phase I portion of the Phase I/II AcSé-ESMART trial were presented at the AACR Annual Meeting […]

Histology slides

AI can predict the risk of distant recurrence in endometrial cancer

18 April 2023

An investigational deep learning model requiring one histopathologic slide accurately predicted the risk of distant recurrence in patients with endometrial cancer, according to findings presented at the AACR Annual Meeting 2023. Endometrial cancer is the most common type of uterine cancer. While patients with early-stage uterine cancer have an approximately 95% five-year survival rate, those […]

Tumour microenvironment

Data shows new therapy successfully targets solid tumours

18 April 2023

Avacta Group has presented pre-clinical data describing the novel pre|CISION proteasome inhibitor, AVA3996, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Florida, US. Proteasome inhibitors are effective anti-cancer drugs that could benefit from application of our preICISION technology to expand their use. While the global proteasome inhibitors market is expected to […]

Myeloma cells

Bispecific antibody has 90% response rate in multiple myeloma

17 April 2023

Patients with relapsed or refractory multiple myeloma who were treated with the two highest doses of REGN5459, a bispecific antibody targeting BCMA and CD3, experienced a 90.5% overall response rate. This is according to results of a Phase I/II clinical trial presented at the AACR Annual Meeting 2023 in Florida. REGN5459 binds to BCMA on […]

Genetics

Patients of African heritage have fewer actionable mutations

17 April 2023

Genomic profiling of patients who were treated for colorectal cancer showed that patients with African ancestry had fewer actionable mutations than patients with European ancestry. These patients were also less likely to qualify for treatment with immunotherapy, according to data presented at the AACR Annual Meeting 2023. “African American patients are known to have worse […]

Medical research

First patient dosed with PI3Kα inhibitor for solid tumours

17 April 2023

Totus Medicines has dosed its first patient in a Phase I clinical trial of TOS-358, a first-in-class covalent PI3Kα inhibitor for the treatment of numerous cancers with known PIK3CA mutations. The Totus Accel Platform is designed to be the first biosearch technology that scans, maps, and decodes new drugs thousands of times faster than traditional […]

""

Cancer research is a ‘team sport’ says AACR President

17 April 2023

Cancer research has always been a team sport. But as cancer science delves ever deeper into chemistry, physics, data science, basic biology, and immunology, all these disciplines need to collaborate to bridge traditional boundaries more effectively, according to the AACR President. “This is an old story with new components. We all need to think much […]

Medical laboratory

Immune checkpoint inhibitor improved survival in rare cancer

16 April 2023

The addition of pembrolizumab (Keytruda) to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer, according to results from the Phase III KEYNOTE-966 clinical trial. The results were presented at the AACR Annual Meeting 2023, held April 14-19 and published in The Lancet. Biliary tract cancers are rare […]

Lung cancer

Therapy represents ‘new treatment paradigm’ for lung cancer

16 April 2023

Patients with treatment-naïve resectable non-small cell lung cancer (NSCLC) who received neoadjuvant durvalumab (Imfinzi) plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival (EFS) and pathological complete response (pCR) compared with those who received neoadjuvant chemotherapy alone. The results from the Phase III placebo-controlled AEGEAN clinical trial were presented at the AACR Annual Meeting […]

Liver cancer

Results revealed for ‘practice-changing’ combination liver cancer therapy

16 April 2023

Adjuvant therapy with atezolizumab (Tecentriq) and bevacizumab (Avastin) increased recurrence-free survival of patients with hepatocellular carcinoma (HCC) following surgical resection or ablation, according to the results from a Phase III trial. The results of the IMbrave050 clinical trial were presented at the AACR Annual Meeting 2023, held April 14-19. The mainstays of curative therapies for […]

« Previous
Next »

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free